A prospective phase II study of prostate-specific antigen-guided salvage radiotherapy and ⁶⁸Ga-PSMA-PET for biochemical relapse after radical prostatectomy - The PROPER 1 trial.

ABSTRACT:

Background and purpose

The treatment of biochemical recurrence (BCR) after prostatectomy is challenging as the site of the recurrence is often undetectable. Our aim was to test a personalised treatment concept for BCR based on PSA kinetics during salvage radiotherapy (SRT) combined with prostate-specific membrane antigen positron emission tomography (PSMA-PET).

Materials and methods

This phase II trial included 100 patients with BCR. PSMA-PET was performed at baseline. PSA was measured weekly during SRT. Initially, 70 Gy in 35 fractions was prescribed to the prostate bed. Radiotherapy was adapted after 50 Gy. Non-responders (PSA still ≥ 0.15 ng/mL) received sequential lymph node irradiation with a boost to PSMA-PET positive lesions, while responders (PSA < 0.15 ng/mL) contin

SUBMITTER: Gunnlaugsson A 

PROVIDER: S-EPMC9305618 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature